Indications of Jardiance have expanded

Changing the Heart Failure Treatment Paradigm

With the addition of emulsion-preserving heart failure indications, the scope of chronic heart failure is expanded to the entire area

A good option for the growing number of HFpEF patients. It will be a basic medicine

View of Jardiance press conference

As the SGLT-2 inhibitor Jardiance expanded its scope to a treatment for chronic heart failure unrelated to heart rate, expectations were also expressed in the clinical field.

 

The medical staff said, "We changed the paradigm of heart failure treatment.

 

There are also non-payment areas, but the burden of drug prices is low, so we are actively using Jardiance as a "non-reimbursement." Beringer Ingelheim Korea and Lilly Korea held a press conference on the 12th to commemorate the expansion of the adaptation of the SGLT-2 inhibitor Jardiance.

 

Kang Seok-min, a professor of cardiology at Yonsei Severance Hospital, and Cho Hyun-jae, a professor of cardiology at Seoul National University Hospital and Yoon Jong-chan, a professor of cardiology at Catholic University, participated as speakers to share the value and significance of Jardiance, a new heart failure treatment option.

 

Jardiance expanded its indication to HFpEF in May, becoming the first drug that can be used for all heart failure.

 

Usually, the ejection rate is reduced by less than 40%, the boundary is 40 to 50%, and more than 50% is considered conservation.

 

There have been no drugs that encompass both reduction and preservation of the ejection rate.

 

This is because many new drugs have not proven their effectiveness in heart failure clinical trials.

 

Jardiance succeeded in achieving a primary efficacy evaluation in EMPEROR-Preserved clinical trials in patients with ejection rate-preserving heart failure.

 

According to clinical trials, the Jardiance group reduced the relative risk of hospitalization due to cardiovascular death or heart failure by 21%.

 

Even in the secondary variable, the relative risk of first and repeated hospitalizations due to heart failure was reduced by 27%, and the reduction of eGFR, an indicator of renal dysfunction, was delayed.

 

Medical staff believed that Jardiance's appearance was very meaningful in a situation where the number of patients with heart failure preserving the ejection rate increased, but there were no suitable drugs.

 

Professor Cho said, "Although patients with heart failure, which accounts for about half of all heart failure patients, have relatively many comorbidities and the number is increasing, there are no treatments, so only symptomatic or comorbid diseases were available." "Jardiance proved its good effect in patients with heart failure exceeding 40% of ejection rate, making it the first treatment to cover the entire spectrum of chronic heart failure left ventricular ejection rate," he said.

 

In an EMPULSE study of patients with acute or non-compensatory CHF, Jardiance also confirmed treatment effects such as death from all causes, reduction of heart failure events, and improvement of heart failure symptoms compared to placebo group.

 

In the sub-analysis, more than 65% of the patient groups showed poor efficacy, but this patient group is an object that needs more research even within heart failure.

 

Professor Yoon said, "More than 65% of the ejection rate can be considered normal, but it is classified as a heart failure patient because it shows signs of heart failure.

 

However, there is also a controversy over whether the group can be viewed as the same as existing heart failure patients, he said.

 

"In-depth research on this group is needed." They agreed that SGLT-2 inhibitors, including Jardiance, changed the paradigm of heart failure treatment.

 

Professor Kang said, "Just as SGLT-2 inhibitors are compared to '21st century Statins', SGLT-2 inhibitors in heart failure treatment are drugs that have changed the paradigm." In the future, there will be a perception that SGLT-2 inhibitors will be installed as basic as statins in the clinical field," he said.

 

"We hope that a medical system will be established to diagnose and manage chronic heart failure early as drugs that can be used in patients preserving the ejection rate are created and the number of patients with chronic heart failure is increasing," he said.